Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
421 to 440 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| ZIABC010015 | The Role of Cellular Receptors Involved in Inflammation and Tumor Progression | 1 | 2023 |
| ZIABC011745 | Development of biologic based therapies for rhabdomyosarcoma | 1 | 2023 |
| P01CA129243 | Targets for Therapy for Carcinomas of the Lung | 12 | 2022 |
| R35CA210085 | Studies on oncoprotein-induced feedback: Basic and therapeutic implications | 5 | 2022 |
| K00CA212474 | Defining the relationship between kinase inhibitor pharmacophores and pro-/anti-targets using in vivo models of colorectal cancer | 3 | 2022 |
| K08CA218901 | Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological Malignancies | 3 | 2022 |
| R35CA197709 | New Ways of Targeting K-Ras | 3 | 2022 |
| F30CA243253 | Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer | 2 | 2022 |
| P30NS047101 | University of California San Diego Neuroscience Microscopy Imaging Core | 2 | 2022 |
| P41GM103493 | A Research Resource for Ultra-sensitive High Throughput Proteomics | 2 | 2022 |
| R01CA160495 | FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma | 2 | 2022 |
| R01CA229624 | Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations | 2 | 2022 |
| T32GM007324 | Institutional National Research Service Award | 2 | 2022 |
| DP2HG010099 | In situ functional genomics to understand transcriptional regulation | 1 | 2022 |
| F31CA247416 | Elucidating fibroblast/immune crosstalk and plasticity in pancreatic ductal adenocarcinoma | 1 | 2022 |
| F31CA257390 | Raf-1 As a Regulator of Glutamine Metabolism | 1 | 2022 |
| F32CA247198 | Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer | 1 | 2022 |
| I01BX002049 | Molecular and Genetic Studies of Bladder Tumorigenesis | 1 | 2022 |
| K08CA222684 | Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy | 1 | 2022 |
| K99CA246084 | Elucidating the role of support signaling in promoting minimal residual disease in mouse models of oncogene-driven lung cancer | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=22